---
title: 'Life Sciences Daily Summary: What Happened on November 11, 2026'
headline: Beam’s sickle cell therapy meets its pivotal-trial goal
description: The day also brought FDA approvals for two drugs, a Phase 3 win in Sjögren’s
  disease and argenx’s proposed $1.15 billion acquisition.
url: https://thebench.bio/news/summaries/2026-11-11
topic: all
date: '2026-11-11'
covers:
- '2026-11-11'
date_published: '2026-11-11T12:04:47Z'
date_modified: '2026-11-12T00:04:45Z'
tags:
- Regulatory
- Clinical
- Software
- Funding
- Industry
- Manufacturing
sources: 18
publisher: TheBench.Bio
---

# Life Sciences Daily Summary: What Happened on November 11, 2026

**Beam’s sickle cell therapy meets its pivotal-trial goal**

The day also brought FDA approvals for two drugs, a Phase 3 win in Sjögren’s disease and argenx’s proposed $1.15 billion acquisition.

## Today in brief

Beam Therapeutics said risto-cel met its primary efficacy goal in a sickle cell trial, which required 12 months without severe pain crises. [1] [2] Amgen’s dazodalibep met the primary endpoint in a Phase 3 Sjögren’s disease trial, and Johnson & Johnson reported a Phase 3 win for Caplyta in bipolar mania. [3] [4]

The FDA approved Merck KGaA’s Pimjetmi for some adults with tenosynovial giant cell tumor and Bayer’s Sunharbo to reduce recurrent stroke risk. [5] [6] [7] Argenx agreed to acquire Unnatural Products for $550 million upfront, plus milestone payments that could lift the price to $1.15 billion. [8] [9]

## Beam’s risto-cel hits its sickle cell trial endpoint

Beam said risto-cel met the primary efficacy endpoint in BEACON, an open-label study of people with severe sickle cell disease. [1] The endpoint required at least 12 consecutive months without severe vaso-occlusive crises, painful episodes caused by blocked blood flow. [1] [2]

By an October 20 data cutoff, 39 adults and 10 adolescents had received treatment, and 31 participants had completed the follow-up required for the endpoint. [1] Beam said the trial also met its primary safety and secondary efficacy endpoints. [1] The company said it may file a biologics license application with the FDA as soon as the end of 2026 and plans to present detailed pivotal-trial data in 2027. [1]

## Dazodalibep meets its Phase 3 endpoint in Sjögren’s disease

Both dazodalibep regimens reduced systemic disease activity more than placebo at week 48 in the 648-person OASIZ-301 trial. [3] With dosing every four weeks, disease activity scores fell by 5.6 points, compared with 3.8 points on placebo. [3]

That regimen also improved patient-reported dryness and stimulated salivary flow compared with placebo. [3] Adverse events reported more often with dazodalibep included infections, hypertension and infusion reactions, generally described as mild to moderate. [3] Serious adverse events and treatment discontinuations were balanced between groups, and malignancy rates were low and similar. [3]

## FDA clears Pimjetmi for certain people with joint tumors

The FDA approved Merck KGaA’s once-daily oral drug Pimjetmi for adults with symptomatic tenosynovial giant cell tumor when surgery could worsen function or cause serious complications. [5] [6] The rare tumor can cause pain and limit movement around affected joints. [5]

In the Phase 3 Maneuver trial, 56% of patients taking pimicotinib had an objective tumor response at week 25, compared with 3% on placebo. [5] [6] The trial also found improvements in range of motion, physical function and pain compared with placebo. [10] Merck reported no evidence of liver toxicity in the pivotal trial. [10]

## Sunharbo wins FDA approval to prevent another stroke

On November 9, the FDA approved Bayer’s asundexian, sold as Sunharbo, with antiplatelet therapy for adults after certain ischemic strokes or high-risk transient ischemic attacks. [7] [11] The approval makes it the first Factor XIa inhibitor approved worldwide, according to the cited account. [7] [12]

In the Phase 3 Oceanic-stroke trial, adding asundexian reduced ischemic stroke by 26% compared with antiplatelet therapy alone, while major bleeding rates were similar to placebo. [7] [12] Bayer said the once-daily pill would launch in the United States in mid-November. [11]

## FDA requires a potential rare-eye-risk warning on GLP-1 labels

On November 9, the FDA directed manufacturers of approved GLP-1 receptor agonists to add a warning about a possible increased risk of non-arteritic anterior ischemic optic neuropathy, a condition that can cause vision loss. [13] [14] The agency advised patients and caregivers to contact a health professional promptly if symptoms arise, and people with a previous episode to discuss whether to continue treatment. [13]

An FDA meta-analysis identified 15 probable cases among trial participants, 10 in people taking a GLP-1 drug and five in placebo recipients. [13] The agency said the combined evidence indicated a possible increased risk. A retrospective study found no statistically significant increase compared with SGLT-2 inhibitors, but did find an association compared with DPP-4 inhibitors. [13]

## Argenx to buy Unnatural Products for up to $1.15 billion

Argenx agreed to acquire Unnatural Products for $550 million upfront, with up to $595 million more tied to development and regulatory milestones. [8] The deal would give Argenx full ownership of the company, where it previously held a minority stake. [8]

Unnatural Products uses AI-assisted compound design, large-scale synthesis and screening to develop macrocyclic peptides. [8] [9] The companies expect the acquisition to close by year-end, subject to customary conditions. They expect the Santa Cruz site to become Argenx’s peptide-discovery hub. [8]

## CVS plans to separate its retail pharmacies from health businesses

CVS Health plans to split into two publicly traded companies, separating its retail pharmacies from a health care business that would retain Aetna, Caremark, CVS Specialty, Oak Street Health and Signify Health. [15] The company expects the separation in the first half of 2028, subject to conditions and final approvals. [15]

The proposed pharmacy company would operate about 9,000 retail locations, while Caremark and CVS Specialty would remain with Aetna in the other business. [15] CVS said the split could give each company more strategic focus and allow the pharmacy business to pursue broader commercial partnerships. [15]

## Tandem recalls Mobi insulin pump after false occlusion alarms

Tandem recalled its Mobi insulin pump after a problem with false occlusion alarms that could interrupt insulin delivery, according to the FDA recall database. [16] Tandem reported 230 adverse events associated with the pump. [16]

## Also worth knowing

- The UK’s MHRA approved retifanlimab with chemotherapy for adults with advanced anal cancer that cannot be removed surgically, has spread or has returned locally. [17]
- Oura plans to acquire Counsel Health for $625 million as wearable companies expand into health care services. [18]

## The day in numbers

- **12 months**: Time without severe pain crises required for risto-cel’s BEACON primary endpoint. [1] [2]
- **56% vs. 3%**: Objective response rates for Pimjetmi and placebo at week 25 in the Maneuver trial. [5] [6]
- **26%**: Reduction in ischemic stroke with Sunharbo plus antiplatelet therapy versus antiplatelet therapy alone. [7] [12]
- **$1.15 billion**: Maximum potential value of argenx’s acquisition of Unnatural Products, including milestone payments. [8]

## Sources

1. [Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial](<https://www.biopharminternational.com/view/beam-risto-cel-primary-endpoint-sickle-cell-trial>), BioPharm International, 2026-11-11
2. [The BioPharm Brief: Base Editing Hits Its Mark in Sickle Cell, a Phase 3 Win in Sjögren’s, and Off-the-Shelf CAR-T in Lupus](<https://www.biopharminternational.com/view/the-biopharm-brief-base-editing-hits-its-mark-in-sickle-cell-a-phase-3-win-in-sj-gren-s-and-off-the-shelf-car-t-in-lupus>), BioPharm International, 2026-11-11
3. [Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial](<https://www.biopharminternational.com/view/amgen-s-dazodalibep-reduces-systemic-disease-activity-in-phase-3-sj-gren-s-trial>), BioPharm International, 2026-11-11
4. [J&J targets Caplyta label expansion on Phase III bipolar mania success  ](<https://www.clinicaltrialsarena.com/news/johnson-johnson-caplyta-bipolar-type-i-phase-iii-success/>), Clinical Trials Arena, 2026-11-11
5. [FDA Approves Pimjetmi for Patients With Tenosynovial Giant Cell Tumor](<https://www.pharmexec.com/view/fda-approves-pimjetmi-patients-tenosynovial-giant-cell-tumor>), Pharmaceutical Executive, 2026-11-11
6. [Pharmaceutical Executive Daily: FDA Approves Pimjetmi](<https://www.pharmexec.com/view/daily-fda-approves-pimjetmi>), Pharmaceutical Executive, 2026-11-11
7. [FDA Approves asundexian for Secondary Stroke Risk Reduction](<https://www.pharmexec.com/view/fda-approves-asundexian-for-secondary-stroke-risk-reduction>), Pharmaceutical Executive, 2026-11-10
8. [Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition](<https://www.genengnews.com/topics/translational-medicine/argenx-expands-immunology-capabilities-with-up-to-1-15b-unp-acquisition/>), GEN, 2026-11-10
9. [The biotech bi-weekly: world-first AI biosecurity lab launched, a new streamlined multiomic imaging system, and new EV media and qPCR master mixes](<https://www.biotechniques.com/drug-discovery-development/the-biotech-bi-weekly-world-first-ai-biosecurity-lab-launched-a-new-streamlined-multiomic-imaging-system-and-new-ev-media-and-qpcr-master-mixes/>), BioTechniques, 2026-11-11
10. [Drug Approval Marks Another Win for Merck KGaA’s Rare Tumor Strategy](<https://medcitynews.com/2026/11/merck-kgaa-emd-serono-pimicotinib-pimjetmi-fda-approval-tgct-rare-tumor/>), MedCity News, 2026-11-11
11. [FDA Approves First-in-Class Bayer Drug for Reducing the Risk of Stroke](<https://medcitynews.com/2026/11/bayer-sunharbo-asundexian-fda-approval-secondary-stroke-prevention-factor-xia-bayry/>), MedCity News, 2026-11-10
12. [Pharmaceutical Executive Daily: FDA Requires Safety Label Update on GLP-1 Receptor Agonist](<https://www.pharmexec.com/view/daily-fda-requires-safety-label-update-glp1-receptor-agonist>), Pharmaceutical Executive, 2026-11-10
13. [FDA Requests Updated Safety Label Warning Across All GLP-1 Receptor Agonist for Potential Risk of NAION](<https://www.pharmexec.com/view/fda-requests-safety-label-warning-glp-1-receptor-agonist-risk-naion>), Pharmaceutical Executive, 2026-11-10
14. [FDA orders blindness risk warning to GLP-1 agonist labels](<https://pharmaphorum.com/news/fda-orders-blindness-risk-warning-glp-1-agonist-labels>), pharmaphorum, 2026-11-10
15. [CVS Health’s Breakup: A Turning Point for Pharma Supply Chains or a Redistribution of Market Power?](<https://www.pharmaceuticalcommerce.com/view/cvs-health-s-breakup-a-turning-point-for-pharma-supply-chains-or-a-redistribution-of-market-power->), Pharmaceutical Commerce, 2026-11-11
16. [Tandem recalls Mobi insulin pump, reports 230 adverse events](<https://www.medtechdive.com/news/tandem-recalls-mobi-insulin-pump-reports-230-adverse-events/874386/>), MedTech Dive, 2026-11-11
17. [MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced anal cancer](<https://www.gov.uk/government/news/mhra-approves-retifanlimab-zynyz-for-the-treatment-of-advanced-anal-cancer>), MHRA, 2026-11-11
18. [Oura makes bet on AI in healthcare with $625M Counsel Health buy](<https://www.medtechdive.com/news/oura-makes-bet-on-ai-in-healthcare-with-625m-counsel-health-buy/874398/>), MedTech Dive, 2026-11-11

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biopharminternational.com/view/beam-risto-cel-primary-endpoint-sickle-cell-trial>
[2]: <https://www.biopharminternational.com/view/the-biopharm-brief-base-editing-hits-its-mark-in-sickle-cell-a-phase-3-win-in-sj-gren-s-and-off-the-shelf-car-t-in-lupus>
[3]: <https://www.biopharminternational.com/view/amgen-s-dazodalibep-reduces-systemic-disease-activity-in-phase-3-sj-gren-s-trial>
[4]: <https://www.clinicaltrialsarena.com/news/johnson-johnson-caplyta-bipolar-type-i-phase-iii-success/>
[5]: <https://www.pharmexec.com/view/fda-approves-pimjetmi-patients-tenosynovial-giant-cell-tumor>
[6]: <https://www.pharmexec.com/view/daily-fda-approves-pimjetmi>
[7]: <https://www.pharmexec.com/view/fda-approves-asundexian-for-secondary-stroke-risk-reduction>
[8]: <https://www.genengnews.com/topics/translational-medicine/argenx-expands-immunology-capabilities-with-up-to-1-15b-unp-acquisition/>
[9]: <https://www.biotechniques.com/drug-discovery-development/the-biotech-bi-weekly-world-first-ai-biosecurity-lab-launched-a-new-streamlined-multiomic-imaging-system-and-new-ev-media-and-qpcr-master-mixes/>
[10]: <https://medcitynews.com/2026/11/merck-kgaa-emd-serono-pimicotinib-pimjetmi-fda-approval-tgct-rare-tumor/>
[11]: <https://medcitynews.com/2026/11/bayer-sunharbo-asundexian-fda-approval-secondary-stroke-prevention-factor-xia-bayry/>
[12]: <https://www.pharmexec.com/view/daily-fda-requires-safety-label-update-glp1-receptor-agonist>
[13]: <https://www.pharmexec.com/view/fda-requests-safety-label-warning-glp-1-receptor-agonist-risk-naion>
[14]: <https://pharmaphorum.com/news/fda-orders-blindness-risk-warning-glp-1-agonist-labels>
[15]: <https://www.pharmaceuticalcommerce.com/view/cvs-health-s-breakup-a-turning-point-for-pharma-supply-chains-or-a-redistribution-of-market-power->
[16]: <https://www.medtechdive.com/news/tandem-recalls-mobi-insulin-pump-reports-230-adverse-events/874386/>
[17]: <https://www.gov.uk/government/news/mhra-approves-retifanlimab-zynyz-for-the-treatment-of-advanced-anal-cancer>
[18]: <https://www.medtechdive.com/news/oura-makes-bet-on-ai-in-healthcare-with-625m-counsel-health-buy/874398/>
